Neurocrine Biosciences Inc vs Welltower Inc. Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Welltower Inc. Common Stock trades at $223.07 (market cap $159.33B). The key difference: Welltower Inc. Common Stock is far larger — about 10.9× Neurocrine Biosciences Inc's market cap, and Welltower Inc. Common Stock pays a 1.54% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Welltower Inc. Common Stock for 0 Days on average.
| NBIX | WELL | |
|---|---|---|
Market Cap | $14.60B | $159.33B |
Volume | 1,075,694 | 2,484,986 |
Sector | Health | Real Estate |
52-Week High | $185.50 | $252.07 |
52-Week Low | $123.10 | $165.94 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $14.61B | $177.09B |
Dividend Yield | — | 1.54% |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Welltower is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, outpatient medical facilities, and other health-related real estate.
Read more on WELL →